Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Robert Wasserman
Articles From This Author
INVESTING
5Â ways allergan can keep up momentum
By Robert Wasserman
Feb 15, 2017 3:03 PM EST
STOCKS
Skin in the game: This dermatology market stock is a good M&A bet
By Robert Wasserman
Nov 4, 2016 12:43 PM EDT
OPINION
How to invest in your favorite MD
By Robert Wasserman
Nov 2, 2016 11:02 AM EDT
STOCKS
Rebound may be in store for beaten-down shares of TherapeuticsMD
By Robert Wasserman
Oct 12, 2016 2:33 PM EDT
STOCKS
Momenta, coherus biosciences are both good options in the biosimilar space
By Robert Wasserman
Oct 5, 2016 9:14 AM EDT
OPINION
Changes at the top for endo could benefit its smaller partners
By Robert Wasserman
Sep 26, 2016 9:03 AM EDT
STOCKS
Applied genetic technologies is an attractive acquisition target for allergan or biogen
By Robert Wasserman
Sep 20, 2016 9:05 AM EDT
STOCKS
2 big companies and 1 small one to target in the pharma/biotech space
By Robert Wasserman
Sep 8, 2016 9:07 AM EDT
STOCKS
ANI Pharmaceuticals' varied offerings, strategic acquisitions make it a good play for investors
By Robert Wasserman
Aug 30, 2016 9:29 AM EDT
STOCKS
This little-known orthopedic-device stock is delivering huge returns
By Robert Wasserman
Aug 29, 2016 12:38 PM EDT
INVESTING
Changing landscape for generic-drug makers creates opportunities
By Robert Wasserman
Aug 8, 2016 2:25 PM EDT
OPINION
Opko Health's many acquisitions add up to varied product offerings and potential growth
By Robert Wasserman
Aug 2, 2016 8:22 AM EDT
OPINION
13 companies to watch from MIT's smart 50 list, including 4 buys
By Robert Wasserman
Jul 21, 2016 7:48 AM EDT
OPINION
NeoGenomics deal with GE's Clarient 6 months later: boom or bust?
By Robert Wasserman
Jul 6, 2016 10:38 AM EDT
OPINION
Opko is a buying opportunity after FDA's approval of kidney drug
By Robert Wasserman
Jun 30, 2016 5:15 PM EDT